Batu Biologics names new chair
This article was originally published in Scrip
Batu Biologics, a San Diego biotechnology company developing cancer angiogenesis-targeting immunotherapeutic product ValloVax, has named Dr Alan Lewis as chair of its board of directors. Dr Lewis has previously been vice-president of research at Wyeth-Ayerst, and CEO at Signal Pharmaceuticals, Novocell, and the Juvenile Diabetes Research Foundation. Most recently he was CEO of Medistem, where he worked with Batu Biologics co-founder Dr Thomas Ichim.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.